Approved regulatory verdict
Evidence outlook
Approved: Chronic Graft-versus-Host Disease
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
How the evidence outlook works ↗
Featured trials The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Chronic Graft-versus-Host Disease · approved · Featured evidence · 2 approved Featured evidence · 2
Competitive landscape 1 competitor in this universe: 0 direct rivals (same mechanism and indication), 1 same-class, 0 same-indication.
Unlock with Research ↗ Drug Stage Modality Mechanism Evidence signal Reported efficacygraded featured trials Axatilimab: this drug Approved Monoclonal antibody CSF-1R Enrupatinib Phase 2 Small molecule CSF-1R
Research Unlock the full comparison Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Unlock with Research ↗ Upcoming events (12 total) Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2026 (2) December 2026 (2) Phase 2 Hodgkin Lymphoma Active not recruiting
Est. primary completion 2026-12 ·
NCT05723055 ·
CT.gov ↗ What to watch Phase 2 TNBC - Triple-Negative Breast Cancer, Breast Cancer Recruiting
Est. primary completion 2026-12-01 ·
NCT05491226 ·
CT.gov ↗ What to watch 2027 (5) January 2027 (1) Phase 1 Breast Cancer Recruiting
Est. primary completion 2027-01-31 ·
NCT06959537 ·
CT.gov ↗ What to watch April 2027 (1) Phase 1/2 Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Recurrent Malignant Solid Neoplasm … Recruiting
Est. primary completion 2027-04-01 ·
NCT06320405 ·
CT.gov ↗ What to watch May 2027 (1) Phase 1 Breast Cancer, PALB2-Mutated Breast Carcinoma, HER2-negative Breast Cancer, BRCA1 Mutation, BRCA2 Mutation Recruiting
Est. primary completion 2027-05-01 ·
NCT06488378 ·
CT.gov ↗ What to watch June 2027 (1) Phase 2 Chronic Graft-versus-host-disease Active not recruiting
Est. primary completion 2027-06-01 ·
NCT06388564 ·
CT.gov ↗ What to watch October 2027 (1) Phase 1/2 Atypical Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic/Myeloproliferative Neoplasm … Recruiting
Est. primary completion 2027-10-31 ·
NCT06523556 ·
CT.gov ↗ What to watch 2028 (1) May 2028 (1) Phase 3 Chronic Graft-versus-host-disease Active not recruiting
Est. primary completion 2028-05-31 ·
NCT06821542 ·
CT.gov ↗ What to watch 2029 (1) August 2029 (1) Phase 1 Acute Myeloid Leukemia, TP53 Gene Mutation Not yet recruiting
Est. primary completion 2029-08-01 ·
NCT07511062 ·
CT.gov ↗ What to watch 2030 (1) May 2030 (1) Phase 2 Chronic Graft Versus Host Disease, cGVHD Recruiting
Est. primary completion 2030-05-05 ·
NCT06663722 ·
CT.gov ↗ What to watch 2031 (1) July 2031 (1) Phase 1/2 Myelofibrosis (MF), Chronic Myelomonocytic Leukemia (CMML) Recruiting
Est. primary completion 2031-07-31 ·
NCT07128381 ·
CT.gov ↗ What to watch 2033 (1) July 2033 (1) Phase 2 TNBC - Triple-Negative Breast Cancer, Breast Cancer Not yet recruiting
Est. primary completion 2033-07 ·
NCT07015853 ·
CT.gov ↗ What to watch See the full readout calendar ↗
All registered studies Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.
All indications (17) Chronic Graft-versus-Host Disease (3) Other / comorbidity (14)
Phase 3 (2) Phase 2 (8) Phase 1/2 (3) Phase 1 (4)